Oral N-acetylcysteine for Retinitis Pigmentosa | MicrobiomeTrials← Back to trialsNCT05537220
Oral N-acetylcysteine for Retinitis Pigmentosa
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2023-10-11Est. Completion: 2029-05
Enrollment target: 485 participants Locations- University of California - Davis, Department of Ophthalmology & Vision Science, Davis, California, United States
- University of Southern California, Keck School of Medicine, Los Angeles, California, United States
- University of California - San Francisco, Department of Ophthalmology, San Francisco, California, United States
- Stanford University, Byers Eye Institute, Stanford, California, United States
- Vitreo Retinal Associates, Gainesville, Florida, United States
- University of Florida - Jacksonville, UF Health Jacksonville, Jacksonville, Florida, United States
- University of Miami, Bascom Palmer Eye Institute, Miami, Florida, United States
- Emory University, Emory Eye Center, Atlanta, Georgia, United States
- University Of Illinois At Chicago, Chicago, Illinois, United States
- Northwestern University, Evanston, Illinois, United States
- University of Iowa, Carver College of Medicine, Iowa City, Iowa, United States
- Wilmer Eye Institute- Johns Hopkins University, Baltimore, Maryland, United States
- Harvard University, Mass. Eye and Ear, Boston, Massachusetts, United States
- University of Michigan, Kellogg Eye Center, Ann Arbor, Michigan, United States
Other microbiome trials you might be interested in
Hepato/Renal Fibrocystic DiseaseAutosomal Recessive Polycystic Kidney DiseaseJoubert SyndromeBardet Biedl SyndromeMeckel-Gruber SyndromeCongenital Hepatic FibrosisCaroli SyndromeOro-Facial-Digital Syndrome Type INephronophthisisGlomerulocystic Kidney Disease
Hepato-renal fibrocystic diseases (HRFD) is a term developed that encompasses rare diseases such as Autosomal Recessive …
Washington D.C., United StatesEst. completion Sep 2030
University of Minnesota, Department of Ophthalmology and Visual Neurosciences, Minneapolis, Minnesota, United StatesMayo Clinic, Department of Ophthalmology, Rochester, Minnesota, United StatesUniversity of Oklahoma, Dean McGee Eye Institute, Oklahoma City, Oklahoma, United StatesScheie Eye Institute, Philadelphia, Pennsylvania, United StatesVanderbilt University, Vanderbilt Eye Institute, Nashville, Tennessee, United StatesRetina Foundation of the Southwest, Dallas, Texas, United StatesUniversity of Utah, Moran Eye Center, Salt Lake City, Utah, United StatesUniversity of Washington, Department of Ophthalmology, Seattle, Washington, United StatesUniversity of Wisconsin - Madison, McPherson Eye Research Institute, Madison, Wisconsin, United StatesMedical College of Wisconsin, The Eye Institute, Milwaukee, Wisconsin, United StatesMedical University of Graz, Department of Ophthalmology, Graz, Styria, AustriaMcGill University, The Research Institute of the McGill University Health Center, Montreal, Quebec, CanadaUniversity of Tübingen, Department für Augenheilkunde, Tübingen, Baden-Wurttemberg, GermanyRadboud University, Radboud University Medical Centre, Nijmegen, Gelderland, NetherlandsUniversity of Amsterdam, Amsterdam Medical Center, Amsterdam, Northern Holland, NetherlandsUniversitätsspital Basel, Eye Clinic, Basel, SwitzerlandUniversity College London, Moorfields Eye Hospital, London, England, United KingdomAMD
Retinal Degeneration
Retinitis Pigmentosa
Background:
\- Best Vitelliform Dystrophy (Best disease), Late-Onset Retinal Degeneration (L-ORD), and Age-Related Macu…